Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China

Anatomical Record

Volumn 293, Issue 10, 2010, Pages 1679-1684

  Chen, Shi Lun ^a   Jiang, Bin ^b   Qiu, Lu Gui ^c   Yu, Li ^d   Zhong, Yu Ping ^a   Gao, Wen ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Bortezomib; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHMA; CHINA; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; HEART ARRHYTHMIA; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; KIDNEY FAILURE; LIVER DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RASH; STOMACH PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957689793     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.21218     Document Type: Article

References (21)

1. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG. 2007. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110:1042-1049. (Pubitemid 47312870)
2. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. 2004. Treatment of multiple myeloma. Blood 103:20-32.
3. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. 1998. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123.
4. Caravita T, Petrucci MT, Spagnoli A, Siniscalchi A, Offidani M, Federico V, Falco P, Rizzo M, Palumbo A, Fabritiis PD. 2007. Neuropathy in multiple myeloma patients treated with bortezomib: a multicenter experience. Blood (ASH Annual Meeting Abstracts) 110: Abstract 4823.
5. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076. (Pubitemid 32691956)
6. International Myeloma Working Group. 2003. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol 121:749-757.
7. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J. 2005. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776-783. (Pubitemid 40904528)
8. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. 2000. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109:89-96. (Pubitemid 30340583)
9. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA. 2007. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92:546-549. (Pubitemid 350144300)
10. Kenealy MK, Prince HM, Honemann D. 2006. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma. Pharmacotherapy 26:1205-1206. (Pubitemid 44167834)
11. Kuehl WM, Bergsagel PL. 2002. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2:175-187.
12. Kumar S, Gertz M, Dispenzieri A, Lacy M, Geyer S, Iturria N, Fonseca R, Hayman S, Lust J, Kyle R, Greipp P, Witzig T, Rajkumar S. 2003. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78:34-39. (Pubitemid 36033958)
13. Ludwig H, Hajek R, Tóthová E, Tóthová E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A. 2009. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113:3435-3442.
14. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR. 2003. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136-1144. (Pubitemid 36323723)
15. Prince HM, Mileshkin L, Schenkel B. 2007. An analysis of clinical trials assessing the efficacy and safety of singleagent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 48:46-55. (Pubitemid 46978623)
16. Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, S. Rajkumar V, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski R, Kuter D, Limentani S, Lee S, Hideshima T, Esseltine D, Kauffman M, Adams J, Schenkein D, Anderson K. 2003. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617. (Pubitemid 36741588)
17. Richardson P, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA. 2009. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518-3525.
18. San Miguel JF, Schlag R, Khuageva NK, San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators. 2008. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917.
19. Terpos E, Politou M, Rahemtulla A. 2004. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 130:623-625. (Pubitemid 39371332)
20. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. 2007. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12:235-239. (Pubitemid 46930250)
21. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. 2003. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19.